UI Hospitals and Clinics
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study
Participants in this study have acute myeloid leukemia (AML) that has relapsed, has been difficult to treat, or is a very difficult to treat type of AML. AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd out the normal cells of the bone marrow. They may flood the bloodstream and invade vital organs. This study is for subjects that would ordinarily be offered a stem cell transplant (SCT; also known as hematopoietic cell transplantation or bone marrow transplant). AML patients might receive a stem cell transplant as part of standard therapy if: --Chemotherapy treatment is not destroying enough of their leukemia cells. This is called -refractory AML-. --Certain genetic factors are found in the blast cells --AML has gone away and then comes back (called relapsed AML).
Victoria Scaccia, 319-356-7875
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.